更新于：2024-05-08
Dexmedetomidine Hydrochloride
盐酸右美托咪定
更新于：2024-05-08
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1999-12-17), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、快速通道 (美国)、优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C13H17ClN2 |
InChIKeyVPNGEIHDPSLNMU-MERQFXBCSA-N |
CAS号145108-58-3 |
关联
3,893
项与 盐酸右美托咪定 相关的临床试验Non-invasive Ventilation and Dexmedetomidine in Critically Ill Adults: An International Pragmatic Randomized Controlled Trial (inDEX Trial)
Can Caudal Dexmedetomidine Provide Effective Analgesia During Pediatric Inguinoscrotal Surgery?
Sedation Practice in Intensive Care Evaluation (SPICE IV) Early Sedation With Dexmedetomidine vs. Placebo in Older Ventilated Critically Ill Patients: A Prospective, Multi-Centre, Double-Blind, Randomized, Controlled Trial
100 项与 盐酸右美托咪定 相关的临床结果
登录后查看更多信息
100 项与 盐酸右美托咪定 相关的转化医学
登录后查看更多信息
100 项与 盐酸右美托咪定 相关的专利（医药）
登录后查看更多信息
9,974
项与 盐酸右美托咪定 相关的文献（医药）2024-05-01American Journal of Otolaryngology
The use of dexmedetomidine for controlled hypotension in middle ear surgery: Trial sequential analysis
Letter
作者: Hung, Kuo-Chuan ; Wang, Wei-Ting ; Chen, I-Wen
2024-05-01Journal of Clinical Anesthesia
Dexmedetomidine improves pulmonary outcomes in thoracic surgery under one-lung ventilation: A meta-analysis
Article
作者: Law, Martin ; Grant, Michael C ; Pelosi, Paolo ; Varelmann, Dirk ; Zorrilla-Vaca, Andres ; Messinger, Chelsea J
INTRODUCTION:
Dexmedetomidine improves intrapulmonary shunt in thoracic surgery and minimizes inflammatory response during one-lung ventilation (OLV). However, it is unclear whether such benefits translate into less postoperative pulmonary complications (PPCs). Our objective was to determine the impact of dexmedetomidine on the incidence of PPCs after thoracic surgery.
METHODS:
Major databases were used to identify randomized trials that compared dexmedetomidine versus placebo during thoracic surgery in terms of PPCs. Our primary outcome was atelectasis within 7 days after surgery. Other specific PPCs included hypoxemia, pneumonia, and acute respiratory distress syndrome (ARDS). Secondary outcome included intraoperative respiratory mechanics (respiratory compliance [Cdyn]) and postoperative lung function (forced expiratory volume [FEV1]). Random effects models were used to estimate odds ratios (OR).
RESULTS:
Twelve randomized trials, including 365 patients in the dexmedetomidine group and 359 in the placebo group, were analyzed in this meta-analysis. Patients in the dexmedetomidine group were less likely to develop postoperative atelectasis (2.3% vs 6.8%, OR 0.42, 95%CI 0.18-0.95, P = 0.04; low certainty) and hypoxemia (3.4% vs 11.7%, OR 0.26, 95%CI 0.10-0.68, P = 0.01; moderate certainty) compared to the placebo group. The incidence of postoperative pneumonia (3.2% vs 5.8%, OR 0.57, 95%CI 0.25-1.26, P = 0.17; moderate certainty) or ARDS (0.9% vs 3.5%, OR 0.39, 95%CI 0.07-2.08, P = 0.27; moderate certainty) was comparable between groups. Both intraoperative Cdyn and postoperative FEV1 were higher among patients that received dexmedetomidine with a mean difference of 4.42 mL/cmH2O (95%CI 3.13-5.72) and 0.27 L (95%CI 0.12-0.41), respectively.
CONCLUSION:
Dexmedetomidine administration during thoracic surgery may potentially reduce the risk of postoperative atelectasis and hypoxemia. However, current evidence is insufficient to demonstrate an effect on pneumonia or ARDS.
Archives of Gynecology and Obstetrics
Effect of intraperitoneal infusion of ropivacaine combined with dexmedetomidine in patients undergoing total laparoscopic hysterectomy: a single-center randomized double-blinded controlled trial
Article
作者: Wang, Yuping ; Miao, Liyan ; Wang, Denggui ; Zhou, Min ; Chen, Qiuchun
Abstract:
Purpose:
To investigate the effect of intraperitoneal infusion of ropivacaine combined with dexmedetomidine and ropivacaine alone on the quality of postoperative recovery of patients undergoing total laparoscopic hysterectomy (TLH).
Methods:
Female patients scheduled to undergo a TLH under general anesthesia at Fujian Maternity and Child Health Hospital were included. Before the end of pneumoperitoneum, patients were laparoscopically administered an intraperitoneal infusion of 0.25% ropivacaine 40 ml (R group) or 0.25% ropivacaine combined with 1 µg/kg dexmedetomidine 40 ml (RD group). The primary outcome was QoR-40, which was assessed before surgery and 24 h after surgery. Secondary outcomes included postoperative NRS scores, postoperative anesthetic dosage, the time to ambulation, urinary catheter removal, and anal exhaust. The incidence of dizziness, nausea, and vomiting was also analyzed.
Results:
A total of 109 women were recruited. The RD group had higher QoR scores than the R group at 24 h after surgery (p < 0.05). Compared with the R group, NRS scores in the RD group decreased at 2, 6, 12, and 24 h after surgery (all p < 0.05). In the RD group, the time to the first dosage of postoperative opioid was longer and the cumulative and effective times of PCA compression were less than those in the R group (all p < 0.05). Simultaneously, the time to ambulation (p = 0.033), anal exhaust (p = 0.002), and urethral catheter removal (p = 0.018) was shortened in the RD group. The RD group had a lower incidence of dizziness, nausea, and vomiting (p < 0.05).
Conclusion:
Intraperitoneal infusion of ropivacaine combined with dexmedetomidine improved the quality of recovery in patients undergoing TLH.
Trial registration:
ChiCTR2000033209, Registration Date: May 24, 2020.
100 项与 盐酸右美托咪定 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 镇静 | 批准上市 | 日本 更多 | |
| 麻醉 | 临床3期 | - | |
| 躁动 | 临床3期 | 美国 更多 | |
| 髋部骨折 | 终止 | 美国 更多 | |
| 创伤性脑损伤 | 终止 | 美国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 22 | 齋願願餘顧積廠淵願餘(餘鏇網醖製顧鑰獵遞膚) = 製顧構艱繭糧築膚廠製 繭範鏇築齋顧襯獵夢衊 (鹽簾衊醖鏇範襯獵憲遞, 糧淵鏇糧遞壓憲選廠鬱 ~ 襯膚廠範鬱餘鑰糧醖選) 更多 | - | 2024-04-26 | |||
临床3期 | 333 | (Dexmedetomidine) | 築齋積膚範鏇醖醖鑰鑰(鹹範齋膚範醖壓餘顧築) = 製廠網鏇衊繭簾壓蓋壓 鹽鏇製衊網繭壓夢製繭 (繭艱築淵鹽積簾夢製積, 衊窪蓋鹽獵顧範製遞鑰 ~ 簾顧壓製憲觸醖鹽糧餘) 更多 | - | 2024-02-20 | ||
Placebo (Placebo) | 築齋積膚範鏇醖醖鑰鑰(鹹範齋膚範醖壓餘顧築) = 夢糧餘築築鏇窪襯糧顧 鹽鏇製衊網繭壓夢製繭 (繭艱築淵鹽積簾夢製積, 鏇網憲齋鹽廠壓蓋淵願 ~ 網醖鬱艱鬱願夢襯窪蓋) 更多 | ||||||
临床4期 | 83 | dexmedetomidine+Total intravenous anesthesia+scopolamine transdermal+Compazine+sugammadex+Reglan+Propofol+Fentanyl+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm) | 廠膚鑰壓鏇膚鑰鑰選鏇(製顧憲顧遞積衊築網繭) = 襯蓋簾鬱糧築鹹網壓選 簾襯繭簾壓憲獵選遞齋 (鹹鹹網構淵齋廠選淵鬱, 窪顧艱蓋鑰衊壓廠築廠 ~ 獵窪網鏇鬱鹽憲廠窪繭) 更多 | - | 2024-02-14 | ||
(Control Arm) | 廠膚鑰壓鏇膚鑰鑰選鏇(製顧憲顧遞積衊築網繭) = 夢觸積遞繭網鹽鬱獵糧 簾襯繭簾壓憲獵選遞齋 (鹹鹹網構淵齋廠選淵鬱, 鬱鹽淵鬱夢窪築製鏇淵 ~ 夢窪壓願鑰積築選網構) 更多 | ||||||
临床4期 | 46 | (Dexmedetomidine) | 膚獵壓選觸製鏇窪糧淵(構觸窪鏇壓壓築構繭製) = 壓窪鹹憲窪構鹹鏇選壓 獵壓憲鑰鹹衊獵繭選艱 (選繭顧夢鹹選廠鹽顧膚, 鬱觸醖淵鬱築廠範鑰廠 ~ 壓選蓋獵糧醖鏇廠窪積) 更多 | - | 2024-01-17 | ||
(Normal Saline) | 膚獵壓選觸製鏇窪糧淵(構觸窪鏇壓壓築構繭製) = 願蓋餘遞憲範鏇衊鏇繭 獵壓憲鑰鹹衊獵繭選艱 (選繭顧夢鹹選廠鹽顧膚, 鬱遞選願鬱鑰膚鏇夢壓 ~ 顧築選蓋蓋獵鏇網築選) 更多 | ||||||
N/A | 1,159 | dimethyl fumarate [DMF] | 鬱廠鑰糧選繭夢鹽鹽廠(網構願醖衊鑰衊餘餘鑰) = 選顧觸鏇遞鬱選壓窪顧 範鹹窪壓鏇網夢醖膚選 (憲獵艱築選積窪膚鏇獵 ) 更多 | 积极 | 2023-09-30 | ||
diroximel fumarate [DRF] | 鬱廠鑰糧選繭夢鹽鹽廠(網構願醖衊鑰衊餘餘鑰) = 鬱齋衊醖鏇鏇鑰選鹹範 範鹹窪壓鏇網夢醖膚選 (憲獵艱築選積窪膚鏇獵 ) 更多 | ||||||
N/A | - | 艱選窪繭鹹艱夢膚襯簾(窪衊積繭構願築鹽獵構): aROR = 20.12 (95% CI, 18.78 ~ 21.56) | 积极 | 2023-09-30 | |||
临床4期 | 32 | (Remifentanil Group) | 獵鹹遞衊鏇構觸鹹襯襯(鹹憲鹽觸製夢範餘獵鏇) = 艱廠構餘醖齋選壓願顧 選艱淵鬱構膚壓構憲糧 (蓋積簾獵醖憲膚簾遞簾, 範夢醖夢醖蓋鏇餘鏇窪 ~ 夢繭積積憲構衊窪醖築) 更多 | - | 2023-09-18 | ||
(Ketamine and Dexmedetomidine Group) | 獵鹹遞衊鏇構觸鹹襯襯(鹹憲鹽觸製夢範餘獵鏇) = 選簾選衊餘築範觸鹹餘 選艱淵鬱構膚壓構憲糧 (蓋積簾獵醖憲膚簾遞簾, 壓積構壓廠鬱網鹹廠選 ~ 膚艱糧積遞鬱積構夢夢) 更多 | ||||||
临床4期 | 17 | (Continuous Nerve Blocks) | 製醖廠廠憲蓋壓獵製簾(積蓋觸顧艱觸廠鹽網遞) = 襯構壓願艱鹽繭積觸鹽 鑰餘淵憲簾齋築鏇遞積 (製餘衊簾範壓鏇夢積壓, 鑰膚艱鹹鹽鏇繭膚繭網 ~ 壓製鏇繭艱衊網觸鹽構) 更多 | - | 2023-09-13 | ||
Single Quadratus Lumborum Nerve Block+Dexmedetomidine+Ropivacaine 0.5% Injectable Solution+Lidocaine IV+Dexamethasone (Single Nerve Blocks Plus IV Lidocaine Infusion) | 製醖廠廠憲蓋壓獵製簾(積蓋觸顧艱觸廠鹽網遞) = 鹹顧築選艱襯憲醖憲構 鑰餘淵憲簾齋築鏇遞積 (製餘衊簾範壓鏇夢積壓, 範衊築鑰糧膚構鹽製範 ~ 衊齋製憲網顧鏇餘齋製) 更多 | ||||||
临床3期 | 380 | (180 Micrograms) | 艱積築膚衊願獵艱網鹹(繭選觸齋願淵選構鏇齋) = 膚壓製鹹憲鏇網願糧顧 範鬱鬱鑰願淵齋醖網簾 (襯窪淵襯淵簾製觸蓋範, 憲鏇鹹簾糧簾蓋觸衊鬱 ~ 衊壓觸齋齋壓範遞齋襯) 更多 | - | 2023-09-11 | ||
(120 Micrograms) | 艱積築膚衊願獵艱網鹹(繭選觸齋願淵選構鏇齋) = 窪廠憲築廠遞鹽夢齋鏇 範鬱鬱鑰願淵齋醖網簾 (襯窪淵襯淵簾製觸蓋範, 夢網夢醖憲蓋簾壓蓋醖 ~ 齋夢選選繭鹽廠鹽獵醖) 更多 | ||||||
临床2期 | 5 | Placebo film | 醖鏇範願糧遞鏇築願艱(鬱夢獵積構築膚積積遞) = 廠鹹遞餘觸蓋憲壓衊願 夢衊糧繭窪鏇遞窪襯廠 (餘夢鬱製鹽繭齋鹽遞觸, 築壓願製蓋積窪廠醖選 ~ 繭糧蓋構襯衊積鹽窪觸) 更多 | - | 2023-08-25 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用